AAPG

Ascentage Pharma Group International operates as a clinical-stage biotechnology company focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. Headquartered in Suzhou, China, with operations in the United States, the company specializes in discovering and developing small molecule drugs that target programmed cell death pathways. The company's lead product candidate, olverembatinib (HQP1351), received conditional approval in China in 2021 for treating chronic myeloid leukemia patients resistant to prior tyrosine kinase inhibitors. Ascentage's pipeline includes lisaftoclax (APG-2575), a BCL-2 inhibitor in Phase II trials for hematologic malignancies, and several other candidates targeting apoptosis and cancer metabolism pathways. The company employs approximately 400 people across its research facilities in Suzhou, Guangzhou, and Rockville, Maryland. In 2019, Ascentage completed its initial public offering on the Hong Kong Stock Exchange, raising significant capital to advance its clinical programs. The company maintains strategic collaborations with major pharmaceutical firms, including licensing agreements for select product candidates in various territories. Ascentage operates under China's National Medical Products Administration regulatory framework and pursues dual development strategies in both Chinese and international markets. The company's research emphasizes precision oncology approaches and biomarker-driven patient selection for its clinical trials.